Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

Enhance patient care by using the only objective, quantitative arterial analysis software validated through histology and based on CTA technology. This innovative tool employs ground-truth histological data to reveal the origins of myocardial ischemia, helping to assess risks for heart attacks and strokes. These critical events are often driven by unstable, non-obstructive plaques within the arteries that remain undetected and unaddressed. Traditional non-invasive diagnostic methods fall short, as they cannot penetrate deep into the arterial walls where heart disease begins to manifest. Elucid is leveraging advanced scientific imaging alongside artificial intelligence to facilitate rapid, reliable, and non-invasive diagnoses, ultimately leading to tailored treatment strategies for cardiovascular conditions and improved patient outcomes. With this histology-validated software, you can evaluate plaque composition and determine the risks of heart attacks and strokes with unmatched precision. This comprehensive, objective visualization of arterial health empowers healthcare providers to devise customized treatment approaches well before a patient arrives for hospital care, significantly enhancing the quality of healthcare delivery.

Description

Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Elucid

Country

United States

Website

elucid.com

Vendor Details

Company Name

Hillo

Country

France

Website

www.hillo.ai/

Product Features

Product Features

Alternatives

Alternatives

OMS Trace Analytics Reviews

OMS Trace Analytics

Objective Medical Systems
Altis Labs Nota Reviews

Altis Labs Nota

Altis Labs